Introduction
Recovery of drugs from oral fluid (OF) collection devices depends on the collection device used. The inclusion of buffer or solvent into the collection system to improve the recovery of drugs from the collection swab dilutes the sample. It is important for users of these devices to understand the drug recovery rates from the device they choose. It is equally important for laboratories testing OF samples to understand drug recovery rates, because recovery from the collection device and sample dilution can affect interpretation and reporting of results.
Workplace OF testing in Australia is accredited by the National Association of Testing Authorities (NATA) to The Australian Standard 'Procedures for specimen collection and the detection and quantitation of drugs in oral fluid (AS 4760-2006)' (1) . In October 2013, an NATA Technical Circular was published that included the requirement for verification of manufacturer's data for OF collection devices used by accredited collection agencies in Australia (2) . It advised that manufacturer's data regarding drug recovery rates and stability of drugs during transport should be verified by an accredited laboratory. If the manufacturer is unable to provide drug recovery data, then validation studies need to be performed. When available, data provided by overseas manufacturers do not always relate directly to the compounds and target (cutoff ) concentrations listed in the Australian Standard.
In Australia, the Dra¨ger DCD5000 swab is provided with a vial of isopropanol for transport to the laboratory. A donor who has produced a 'non-negative' on-site screening result is instructed to provide a second sample by swabbing their mouth until the adequacy indicator on the swab stem turns blue. The swab is then discharged into the vial of isopropanol. Samples are forwarded to the laboratory at ambient temperature for confirmatory analysis by mass spectrometry. The purpose of the isopropanol is to increase drug stability during transport and to aid in recovery of drugs from the swab. Kit inserts provided with DCD5000 devices contain some manufacturer's data for methanol as a transport medium.
Data on the recovery of drugs from the DCD5000 swab used with isopropanol and collection volume precision were not available from Dra¨ger Safety Pacific. No peer-reviewed literature was found detailing DCD5000 collection volume, imprecision or drug recovery using isopropanol for the drugs of abuse listed in AS4760-2006.
Knowledge of the volume of OF collected by the swab is important in the measurement and reporting of drugs, particularly with respect to the dilution factor introduced by the isopropanol (or other transport medium, depending on the device). AS4760 requires laboratories to report results as ng/mL of neat OF, rather than ng/mL of OF/buffer solution. Some laboratories weigh each sample and subtract the mean weight of an unused device in order to estimate the volume of OF collected. Drug analysis results are then adjusted to account for the volume of OF and transport medium to give a final concentration of drug in neat OF, assuming that 1 g of OF ¼ 1 mL of OF (3, 4) . Our laboratory incorporates the collection volume imprecision of the device into the uncertainty of measurement of our OF assays, while using a theoretical dilution factor for all samples based on the device type.
This series of experiments investigated the recovery of drugs listed in AS4760-2006, namely: amphetamine, methylamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethylamphetamine (MDMA), 6-acetylmorphine, morphine, codeine, cocaine, benzoylecgonine, ecgonine methyl ester and delta-9-tetrahydrocannabinol (delta-9-THC) from the Dra¨ger DCD5000 device using the isopropanol transport medium provided by the manufacturer. Recovery of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), buprenorphine and norbuprenorphine and collection volume imprecision were also investigated.
Experimental
Chemicals and reagents HPLC grade methanol, acetonitrile and hexane were purchased from Merck (Darmstadt, Germany). Analytical grade ethyl acetate was purchased from Univar Australia Pty Ltd (NSW, Australia).
Deionized water was obtained from a Milli-Q system with a minimum resistivity of 18 mV (Merck Millipore, NSW, Australia). Reference standards and deuterated internal standards were purchased from Cerilliant (TX, USA) through Novachem (VIC, Australia). DCD5000 swabs and isopropanol vials were purchased from Dra¨ger Safety Pacific Pty Ltd (VIC, Australia). The swab storage tubes were purchased from Stratech Scientific APAC Pty Ltd (NSW, Australia).
Standards, calibrators and controls
Calibrators and controls were prepared in a 1 : 1 methanol : water solution (blank calibrator solution) and stored at 2208C prior to analysis. The calibration ranges for 6-acetylmorphine, delta-9-THC, buprenorphine and norbuprenorphine were 5-100 ng/mL, and for all other compounds were 15 -300 ng/mL. Quality control materials were prepared at two concentrations: the target (cutoff ) concentration and double the target concentration. Target concentrations for the AS4760:2006 drugs and the laboratory assigned target concentrations for methadone, EDDP, buprenorphine and norbuprenorphine are listed in Table I . Deuterated internal standards were used for all compounds. Internal standard working solutions were prepared in a 1 : 1 methanol : water solution.
Experimental design Drug-free OF was collected from a single volunteer via passive drooling over 10 min. The pool of drug-free OF was fortified at two concentrations (Table I ) on the day of collection. Delta-9-THC was fortified at 20 and 50 ng/mL. Concentrations higher than the AS 4760 cutoff were chosen for delta-9-THC to eliminate assay variation at lower concentrations due to OF dilution by the isopropanol in the collection system. All other drugs were fortified at their target concentrations (Concentration 1) and double the target concentrations (Concentration 2). Both concentrations of the fortified OF were analyzed in duplicate as controls (not collected onto swabs). Each concentration was then sampled from a beaker using the Dra¨ger DCD5000 swab device (eight replicates per concentration). Sampling was stopped once the adequacy indicator turned blue to indicate the uptake of OF onto the swab was complete (5). Each device was weighed before and after sampling to assess collection volume imprecision. After sampling and weighing, the swabs were discharged from the devices into vials of isopropanol according to the manufacturer's instructions. The isopropanol/swab vials were mixed and incubated at room temperature for 1 h. After incubation, the swabs were transferred to a swab storage tube and centrifuged at 4,200 rpm for 5 min. The liquid from the centrifuged swab was combined with the remaining isopropanol in the original tube, centrifuged again at 4,200 rpm for 5 min and the supernatant analyzed.
Sample preparation Delta-9-THC was analyzed following liquid -liquid extraction (6) . Results were back-calculated post analysis to account for the collection kit dilution.
All other compounds were subjected to online solid-phase extraction (SPE) on a Shimadzu Prominence HPLC system. The collection kit dilution was accounted for at the time of sample preparation. Assays for all compounds were validated within the laboratory and found to be satisfactory for use with the isopropanol/ OF sample solution. The total imprecision for each compound was 10%, with the exception of buprenorphine (13%).
Prior to online SPE, calibrators and controls were mixed with isopropanol and blank OF on the day of sample preparation to simulate collection kit dilution (50 mL of calibrator/control, 50 mL of blank OF and 150 mL of isopropanol). The fortified OF control was prepared in a similar fashion (50 mL of fortified OF was combined with 150 mL of isopropanol and 50 mL of blank calibrator solution). For recovery samples, 200 mL of the collected sample was combined with 50 mL of blank calibrator solution. Calibrators, controls, fortified OF controls and recovery samples were then diluted with 20 mL of an internal standard working solution and 150 mL of 5 mM ammonium acetate in water : methanol : acetonitrile 4 : 1 : 1.
Instrumental and chromatographic conditions
Samples were analyzed on a triple quadrupole mass spectrometer (ABSciex 5500 QTRAP) coupled with a Shimadzu Prominence UFLC system. Positive electrospray ionization mode and multiple reaction monitoring were used for all compounds. Mobile phase A was 5 mM ammonium acetate in deionized water and mobile phase B was 5 mM ammonium acetate in 1 : 1 methanol : acetonitrile. The flow rate was set at 0.27 mL/min and the column oven temperature was 558C. Both methods used a Thermo Scientific Aquasil C18 5 mm 100 Â 2.1 mm reversedphase analytical column and a 25-mL injection volume. The online SPE trap cartridge was a Thermo Scientific Aquasil C18 5 mm 10 Â 2.1 mm drop-in guard. Data were collected using an ABSciex Analyst software (version 1.5) and results were quantitated using AbSciex Multiquant (version 2.1).
For delta-9-THC measurement, the specimen was eluted from the analytical column using a gradient in an analysis time of 7 min. The starting conditions were 40% mobile phase B which was increased to 95% over 1.3 min then held until 4 min when the column was re-equilibrated at 40% B. For all other compounds, the sample was held on the SPE trap cartridge and the mobile phase gradient increased from 1 to 3% B from 0 to 0.6 min while unwanted material was flushed to waste. The sample was then directed to the analytical column where compounds were eluted using a gradient. The gradient was increased in a step-wise fashion as follows: 10% B between 0.6 and 2 min, 55% B between 2 and 5.5 min, and 80% B between 5.5 and 6.5 min. Eighty percent B was held until 12.5 min before being reduced to 1% B. While re-equilibrating the analytical column at 1% B, a secondary pump back-flushed the trap cartridge at 60% B. The total analysis time was 16 min.
Results and discussion

Collection volume precision
The product insert for the DCD5000 claims the swab will collect ' 400 mL' of OF. Collection instructions provided by the manufacturer state that the swab collects 380 mL of OF, and that the swab is combined with 1.5 mL of isopropanol to deliver approximately a one in five diluted sample for laboratory testing.
Devices were weighed before and after the uptake of OF from a beaker to investigate the collection volume imprecision. The imprecision was good with a CV% of 1.3 (n ¼ 16); however, 28% more OF was collected than the product information claimed. The mean volume collected was 487 mL (SD 6.3 mL).
In addition, five volunteers each collected OF onto a swab as per the manufacturer's instructions to investigate in vivo OF uptake. Devices were weighed before and after sampling. The mean volume of OF collected was 467 mL (SD 63 mL) with a range of 387 -535 mL. In vivo imprecision was 13.5% (n ¼ 5).
The isopropanol vials were weighed prior to addition of the DCD5000 swabs (n ¼ 16). The mean weight of the vials was 6.16 g (SD 0.06 g, CV 1%). An empty vial weighed 4.95 g. The mean weight of isopropanol in the vials was calculated to be 1.21 g. When the specific gravity of isopropanol (0.786 at 208C) was taken into account, the mean volume of isopropanol in the vials was 1.54 mL.
Dilution of 500 mL in 1.5 mL of isopropanol constitutes a one in four dilution. Therefore, a 1 in 4 dilution, rather than the 1 in 5 dilution indicated by the manufacturer, was used for the recovery experiment. The variation observed when samples were collected in vivo should be considered by laboratories when reporting results from samples collected with the DCD5000 device.
Drug recovery from the swab Results of the recovery experiment (Table II) are the mean of all replicates analyzed. Each concentration of the fortified pool was assayed neat in duplicate. Samples collected by the device were assayed in singlicate (n ¼ 8 per concentration). The recovery percentage was determined by comparison of the average concentration of the collected samples with that of the fortified pool controls. The between-sample CVs for each compound were ,10%. Recovery ranged from 86 to 102%, with the exception of EDDP. Recovery of EDDP was poor at both concentrations (45% recovery compared with the fortified pool controls).
Decreased recovery from collection devices may lead to EDDP falling below the laboratory's reporting cutoff. EDDP, a metabolite of methadone, is not found in large quantities in OF (7) . Methadone can be prescribed as an oral solution and subjects on a drug treatment program may use the solution to mimic compliance, either by adulterating a urine sample or taking methadone orally immediately prior to OF collection (8) . EDDP is present in much larger quantities in urine, and its presence is recommended to substantiate methadone use (9) . Therefore, urine may be the best sample to collect to prove ongoing use of methadone in scenarios such as a drug treatment program.
Conclusion
Recovery of drugs from the DCD5000 device using the isopropanol vial provided by the manufacturer was acceptable (.85%) for all compounds in the Australian OF workplace testing standard (AS 4760-2006). Buprenorphine, norbuprenorphine and methadone were also found to have acceptable recovery (.93%). EDDP was not adequately recovered from the device using isopropanol (45% recovery). Collection volume imprecision of the DCD5000 swab was good (CV 1.28%), but the swabs collected 28% more OF than the manufacturer claimed.
Oral fluid device users should understand the limitations of the device they use, including the significance of drug recovery from the device. Users should be encouraged to request devicespecific data from the manufacturer for the drugs they intend to test. It is important for laboratories to conduct recovery studies where peer-reviewed literature is unavailable. Where possible, recovery studies should include drugs of interest at concentrations relevant to reporting cutoffs. Collection devices should also be evaluated for collection volume imprecision when the manufacturer cannot provide data to substantiate their claims. Both drug recovery and OF collection volume can impact on a laboratory's reporting of results and should not be unknowns in the testing process. 
